Synalar, a Symbol of Progress in Dermatology

The discovery and development of halogenated corticosteroids in the second half of the 20th century revolutionized the treatment of inflammatory and allergic skin conditions. Among these advancements, Synalar, a topical corticosteroid based on fluocinolone acetonide, emerged as a milestone in dermatology. First synthesized in 1957 by the pharmaceutical laboratory Syntex, based in Palo Alto, California, and developed at its research center in Mexico City, Synalar marked a turning point in the management of skin disorders. This article reviews the history of Synalar, its impact on medicine, and its enduring relevance in the pharmaceutical market.
 
Origins: Syntex and Innovation in Corticosteroids
 
In the 1950s, corticosteroid research was in full swing, driven by the discovery of cortisone and its therapeutic applications. However, early corticosteroids had limitations, such as low potency and significant systemic side effects when applied topically. Syntex, a pioneering company in steroid chemistry, set out to overcome these barriers. Founded in 1944 in Mexico and later established in Palo Alto, Syntex had already gained recognition for its advances in synthesizing steroid hormones, including progesterone.
 
In 1957, Syntex scientists, working in their research department in Mexico City, successfully synthesized fluocinolone acetonide, a synthetic derivative of hydrocortisone. The key to their innovation was the incorporation of a fluorine atom at position 9 of the steroid nucleus, significantly enhancing the compound’s potency. This chemical modification not only boosted the corticosteroid’s anti-inflammatory, antipruritic, and vasoconstrictive activity but also minimized systemic absorption, making it ideal for topical use. The resulting compound was named fluocinolone acetonide, and Syntex marketed it under the brand name Synalar in 1959, becoming one of the first halogenated corticosteroids available on the market.
 
Synalar: A Breakthrough in Dermatological Treatment
 
Synalar was initially introduced in concentrations ranging from 0.01% to 0.025%, designed to treat a wide variety of inflammatory, allergic, and pruritic skin conditions. Its ability to relieve symptoms such as redness, itching, inflammation, scaling, and crusting quickly made it a drug of choice for disorders like atopic dermatitis, psoriasis, eczema, contact dermatitis, lichen planus, and discoid lupus erythematosus.
 
Fluocinolone acetonide, classified as a potent grade III corticosteroid, offered superior efficacy compared to earlier corticosteroids like hydrocortisone, thanks to its greater affinity for glucocorticoid receptors and localized action. Additionally, its formulation in cream, ointment, solution, shampoo, and oil allowed it to meet diverse clinical needs, from scalp applications to the treatment of extensive lesions. Synalar’s versatility, combined with its efficacy, positioned it as a leader in the dermatological market.
 
Synalar also stood out for its use in combinations with other active ingredients, such as neomycin (Synalar-Neo), an antibiotic that addresses secondary bacterial infections in dermatoses, or with agents like ciprofloxacin in otic preparations. These formulations expanded its therapeutic scope, including conditions like external otitis and inflamed hemorrhoids.
 
Impact and Evolution in Dermatology
 
The launch of Synalar marked a paradigm shift in dermatology. Before its arrival, treatments for inflammatory skin conditions were limited and often required systemic therapies with higher risks of adverse effects. Synalar provided a safe and effective alternative, enabling physicians to treat localized conditions with minimal systemic absorption. Its success inspired the development of other halogenated topical corticosteroids, solidifying Syntex’s position as a leader in the pharmaceutical industry.
 
Over the decades, Synalar remained relevant due to its proven efficacy and safety profile when used as directed. Clinical studies and reviews have supported its utility in managing recalcitrant dermatoses, although clear precautions have been established, such as avoiding prolonged use in children, on large areas, or under occlusive dressings, due to risks of skin atrophy, hypopigmentation, or suppression of the hypothalamic-pituitary-adrenal axis.
 
The drug has also undergone commercial adaptations. In addition to its classic presentations, Synalar has been marketed under names like Fluocid Forte, Gelidina, and Synalar Gamma, and in combinations such as Synalar Rectal for hemorrhoids. Its availability in various concentrations and formats has allowed for personalized treatment based on the severity of the condition and the patient’s sensitivity.
 
Current Relevance and Legacy
 
More than six decades after its launch, Synalar remains a cornerstone in dermatology. Despite the emergence of new topical corticosteroids and biologic treatments, Synalar’s cost-effectiveness, versatility, and efficacy keep it a preferred choice for physicians and patients. In many countries, it is available both in generic form and under commercial brands, ensuring its accessibility.
 
Synalar’s legacy extends beyond its clinical impact. It represents Syntex’s success as a pioneer in steroid research and serves as an example of how chemical innovation can transform medical practice.
 
Synalar is, therefore, much more than a medication: it is a symbol of progress in dermatology. From its synthesis in 1957 to its continued use in the 21st century, it has alleviated the suffering of millions of patients with inflammatory and allergic skin conditions. Despite the challenges associated with topical corticosteroids, its efficacy, versatility, and safety, when used correctly, have cemented its status as a leader in its field.
 
Synalar’s impact endures, not only in pharmacies and clinics but also in the history of pharmaceutical innovation, proving that a well-executed discovery can withstand the test of time.
 

A journey through the history of the pharmaceutical industry and one of its great laboratories that had its origins in Alfred Nobel...
“From Alfred Nobel to AstraZeneca”: https://a.co/d/9svRTuI

Innovation for acne-prone skin

Spanish pharmaceutical company Reig Jofre has unveiled the launch of Vincobiosis Acneic, an innovative range of topical products that blends science and nature to care for acne-prone skin.

This new line, designed and developed by Reig Jofre’s innovation team, is centered around Canonia Allysis, a unique plant-derived biotechnological ingredient. Obtained through an advanced process leveraging Vytrus Biotech technology, it harnesses the natural defense mechanisms certain plants use to combat bacterial infections and external threats.
 
Clinical studies have shown that Vincobiosis Acneic effectively reduces blemishes on acne-prone skin in a natural and gentle way, preserving the skin’s ecosystem without disrupting beneficial microorganisms.
 
Initially, this groundbreaking product will be introduced in Spain through medical representative channels and pharmacies. Throughout 2025, it will expand to other international markets via Reig Jofre’s subsidiaries and licensing agreements with partner laboratories.
 

A journey through the history of the pharmaceutical industry and one of its great laboratories that had its origins in Alfred Nobel...
“From Alfred Nobel to AstraZeneca” (Vicente Fisac, Amazon) is available in e-Book and print editions: https://a.co/d/9svRTuI

Reig Jofre + LEO Pharma: Boost for psoriasis treatment…

The pharmaceutical companies Reig Jofre and LEO Pharma have entered into an agreement to provide access to an innovative psoriasis treatment. This agreement aims to enhance the promotion of LEO Pharma’s groundbreaking treatment for mild to moderate psoriasis within the Primary Care sector in Spain. 

Psoriasis is one of the most prevalent dermatological conditions, and specialists in Family and Community Medicine play a key role in its diagnosis and management. In the market for topical psoriasis treatments, this drug stands out as the undisputed leader in both Spain and Europe. Supported by guidelines from leading medical societies (SEMFyC, SEMERGEN, and SEMG), it combines calcipotriol, a vitamin D analog, with betamethasone dipropionate. This unique combination significantly improves the antipsoriatic response and has been recognized by Farmaindustria as an incremental innovation, thanks to its advanced foam formulation. Furthermore, it is the only dermatology drug in the national health system to receive this distinction, highlighting its therapeutic relevance and acceptance among dermatology specialists.
 

A journey through the history of the pharmaceutical industry and one of its great laboratories that had its origins in Alfred Nobel...
“From Alfred Nobel to AstraZeneca”: https://a.co/d/9svRTuI

Rosacea: When art illuminates reality

As part of Rosacea Awareness Month, Galderma, a leading pharmaceutical company, has launched a campaign to raise awareness about rosacea, a condition affecting approximately 415 million people worldwide, shedding light on its physical and emotional impact.
 
Portraits of Rosacea: Where Art Meets Humanity
 
The Portraits of Rosacea project brings together five talented Spanish artists—María Hesse, Álex de Marcos, Ana Jarén, Elena Pancorbo, and María Bueno—with the stories of five individuals living with this condition. Through a process of deep listening, the artists have crafted works that go beyond physical appearances, capturing the emotions, struggles, insecurities, and triumphs of the patients with empathy and sensitivity.
 
Beyond the Skin: The Impact of Rosacea
 
Rosacea manifests as redness, bumps, sensitivity, and discomfort such as itching or burning. However, its effects often extend far beyond the skin, leading to social isolation, embarrassment, and a significant toll on self-esteem. This campaign aims to highlight all aspects of the disease—both its medical challenges and its emotional weight.
 
Diagnosis and Support: A Path to Well-Being
 
A key goal of this initiative is to encourage those who suspect they may have rosacea to consult a dermatologist. Too often, due to lack of awareness or stigma, individuals resort to self-treatment or dismiss their symptoms, delaying care that could halt the disease’s progression and enhance their quality of life.
 
Dr. Adrián Alegre, a dermatologist, emphasizes: “Rosacea is not just redness, itching, or bumps—it’s also insecurity, frustration, and sometimes fear. Seeing a dermatologist can be life-changing: it helps identify the condition, understand its triggers, access proper care and treatments, and rebuild confidence. Managing rosacea is about more than skin—it’s about self-esteem and feeling comfortable in your own body.”
 
What Is Rosacea?
 
Rosacea is a chronic inflammatory skin condition primarily affecting the central areas of the face: cheeks, nose, chin, and forehead. It is characterized by persistent redness, telangiectasias (small visible blood vessels, often called spider veins), acne-like inflammatory lesions, and symptoms such as stinging, burning, dryness, or ocular discomfort. Its visibility on the face can profoundly impact the quality of life and mental health of those affected.
 
While the exact causes of rosacea remain under investigation, several triggers are known to exacerbate it, including spicy foods, alcohol, stress, sun exposure, sudden temperature changes, intense exercise, or an elevated presence of the Demodex mite on the skin. Without proper treatment, rosacea tends to worsen over time.
 
A Call to Action
 
Individuals who suspect they may have rosacea are urged to seek a dermatologist for an accurate diagnosis and tailored treatment plan. Understanding and managing the condition not only alleviates physical symptoms but also paves the way to restored confidence and emotional well-being.
 

A journey through the history of the pharmaceutical industry and one of its great laboratories that had its origins in Alfred Nobel...
“From Alfred Nobel to AstraZeneca”: https://a.co/d/9svRTuI